Coronavirus (COVID-19) Update
AmerisourceBergen and our global businesses are highly engaged during the ongoing spread of the novel COVID-19 “Coronavirus."
Read our latest update

US Bioservices is now dispensing VOSEVI

July 28, 2017

The U.S. Food and Drug Administration has approved VOSEVI (sofosbuvir, velpatasir, and voxilaprevir) for the re-treatment of adult patients with chronic hepatitis C (HCV) infection in adults with genotypes 1-6 previously treated with NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor.